for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cleveland BioLabs, Inc.

CBLI.OQ

Latest Trade

2.29USD

Change

0.11(+5.05%)

Volume

39,604

Today's Range

2.17

 - 

2.41

52 Week Range

0.50

 - 

5.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.18
Open
2.19
Volume
39,604
3M AVG Volume
26.43
Today's High
2.41
Today's Low
2.17
52 Week High
5.00
52 Week Low
0.50
Shares Out (MIL)
12.92
Market Cap (MIL)
28.94
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Cleveland Biolabs Files For Mixed Shelf Of Up To $50 Million

Cleveland Biolabs Inc Says Yakov Kogan Tendered His Resignation As CEO Of Co, Effective Dec.13

Cleveland Biolabs Q1 Loss Per Share $0.08 Excluding Items

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Industry

Biotechnology & Drugs

Contact Info

73 High St

BUFFALO, NY

14203-1149

United States

+1.716.8496810

http://www.cbiolabs.com/

Executive Leadership

Langdon L. Miller

President

Christopher Zosh

Principal Financial Officer, Principal Accounting Officer, Vice President - Finance

Andrei V. Gudkov

Chief Scientific Officer

Ivan Fedyunin

Director

Alexander Andryushechkin

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
27.01
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-85.15

Latest News

Latest News

BRIEF-Cleveland Biolabs Says Entered Into Agreement For Sale Of 1.5 Mln Shares

* CLEVELAND BIOLABS - ENTERED INTO AGREEMENT FOR ISSUANCE AND SALE OF 1.5 MILLION SHARES OF COMMON STOCK AT $2.0945 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Cleveland Biolabs Files For Mixed Shelf Of Up To $50 Million

* CLEVELAND BIOLABS INC FILES FOR MIXED SHELF OF UPTO $50 MILLION - SEC FILING Source text: (https://bit.ly/2ZuyZLt) Further company coverage:

BRIEF-Cleveland Biolabs Gets Nasdaq Extension To Regain Compliance With Listing Rule

* CLEVELAND BIOLABS - ON MAY 1, NASDAQ HEARINGS PANEL GRANTED CO FURTHER EXTENSION TO AUG 17 IN WHICH TO REGAIN COMPLIANCE WITH NASDAQ LISTING RULE Source text: https://bit.ly/2WnJfC1 Further company coverage:

BRIEF-Cleveland Biolabs Reports Quarterly Loss Per Share Of $0.11

* CLEVELAND BIOLABS INC - REVENUE FOR Q1 OF 2018 DECREASED TO $0.2 MILLION COMPARED TO $0.6 MILLION FOR Q1 OF 2017

BRIEF-Cleveland Biolabs Says Received Formal Notification From EMA

* CLEVELAND BIOLABS - RECEIVED DAY 120 REVIEW QUESTIONS FROM EMA REGARDING MARKETING AUTHORIZATION APPLICATION FOR ENTOLIMOD

BRIEF-Cleveland Biolabs Reports Qtrly Loss Per Share $0.10

* CLEVELAND BIOLABS-ESTIMATES CASH,CASH EQUIVALENTS,SHORT-TERM INVESTMENTS AS OF DEC 31 ENOUGH TO FUND OPERATIONS FOR AT LEAST 1 YEAR AFTER 10-K FILING DATE Source text: (http://bit.ly/2FXHEdA) Further company coverage:

BRIEF-Cleveland BioLabs reports Q3 ‍net loss per share, excluding minority interests, $0.11

* Cleveland BioLabs reports third quarter 2017 financial results and development progress

BRIEF-Cleveland BioLabs Q2 loss per share $0.50

* Cleveland BioLabs reports second quarter 2017 financial results and development progress

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up